Population pharmacokinetic analysis of tacrolimus early after Chinese pediatric liver transplantation

Abstract

A population PK model of TAC was developed in Chinese pediatric patients early after liver transplantation. It identified significant relationships between the PK of TAC and the characteristics of the patients. POD, ALT, and TP were identified as the main factors influencing the PK of TAC. The developed model could be useful to optimize individual pediatric TAC dosing regimen in routine clinical practice.

Population pharmacokinetics of tacrolimus in paediatric systemic lupus erythematosus based on real-world study

“…[6][7][8][9][10][11][12][13][14][15] However, tacrolimus has a narrow therapeutic window and displays considerable interindividual and intra-individual variabilities in its pharmacokinetics, with poor correlation between drug dosage and blood concentrations, making it difficult to define an optimal dose schedule. 18 Currently, different tacrolimus PPK models have been set up for various populations including renal transplant patients, [19][20][21][22][23][24] liver transplant patients, [25][26][27][28][29][30] haematopoietic stem cell transplant patients 31 and lung transplant patients. Moreover, the population analysis methodology differentiates between interindividual variability and residual unexplained variability.…”

“…28,33,34 The PK parameters of tacrolimus, TA B L E 2 Drug combination CL/F and V/F, were estimated by NONMEM. Ka was fixed to 4.48 h −1 according to previously reported results.…”

Population pharmacokinetics and Bayesian estimation of tacrolimus exposure in Chinese liver transplant patients

“…MAP has the following advantages: patient characteristics can be incorporated into the model to improve the prediction of individualized AUC; the predictive performance can be improved with additional data; the sampling time can be chosen flexibly; and different PK parameters can be predicted simultaneously. Different TAC PPK models have been established in various populations including renal transplant patients, liver transplant patients, hematopoietic stem cell transplant patients and lung transplant patients . Some studies have tried to estimate TAC AUC using MAP.…”

“…Some studies have tried to estimate TAC AUC using MAP. Some other TAC PPK studies focused on Chinese liver transplant patients . However, they only used conventional TDM data for modelling and assaying the individualized PPK parameters assay rather through Bayesian estimation.…”

Identification of Factors Affecting Tacrolimus Trough Levels in Latin American Pediatric Liver Transplant Patients

“…Previous reports have described a significant association between variability in tacrolimus C0 and the development of acute rejection and adverse drug reactions . Furthermore, other factors, including time after transplant, body weight, hematocrit, age, liver function parameters, and type of graft, contribute to the pharmacokinetic variability in pediatric liver transplant patients …”